Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

82.86 +0.14 (+0.18%)
Streaming Delayed Price Updated: 9:55 AM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.6% in the afternoon session after the company provided strong 2026 financial guidance that surpassed analyst... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead
Since January 2021, the S&P 500 has delivered a total return of 83.6%. But one standout stock has nearly doubled the market - over the past five years, ANI Pharmaceuticals has surged 147% to $77.55 per... 
Via StockStory
Topics Stocks Supply Chain
News headline image
6 Analysts Have This To Say About ANI Pharmaceuticals ↗
 
Via Benzinga
News headline image
4 Analysts Have This To Say About ANI Pharmaceuticals ↗
 
Via Benzinga
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over... 
Via StockStory
Topics Stocks
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
1 Russell 2000 Stock to Consider Right Now and 2 We Avoid
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From ANI Pharmaceuticals’s Q3 Earnings Call
ANI Pharmaceuticals delivered a third quarter marked by substantial year-over-year growth, with management attributing performance to strong momentum across its Rare Disease and Generics segments. CEO... 
Via StockStory
Topics Earnings
News headline image
Generic Pharmaceuticals Stocks Q3 Recap: Benchmarking ANI Pharmaceuticals (NASDAQ:ANIP)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time ↗
The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time 
Via The Motley Fool
News headline image
ANIP Q3 Deep Dive: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 53.6% year on year to $227.8 million. The... 
Via StockStory
News headline image
ANI PHARMACEUTICALS INC (NASDAQ:ANIP) Reports Record Q3 2025 Earnings, Beating Estimates ↗
ANI Pharmaceuticals (ANIP) smashed Q3 2025 earnings estimates, posting record revenue and a 14% EPS beat. The company also raised its full-year 2025 guidance. 
Via Chartmill
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Strong Q3 Numbers, Stock Soars
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 53.6% year on year to $227.8 million. The... 
Via StockStory
News headline image
Examining the Future: ANI Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
Earnings Scheduled For November 7, 2025 ↗
 
Via Benzinga
News headline image
3 Profitable Stocks We’re Skeptical Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Screens as High Growth Momentum Stock Meeting Minervini Trend Template ↗
ANI Pharmaceuticals (ANIP) combines strong technical uptrend with explosive earnings and sales growth, fitting a proven strategy for spotting potential market leaders. 
Via Chartmill
News headline image
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Combines Strong Growth Momentum with Bullish Technical Setup ↗
ANI Pharmaceuticals (ANIP) shows strong growth momentum with 76% EPS growth and a positive technical setup, signaling a potential breakout opportunity. 
Via Chartmill
News headline image
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q2 Earnings?
ANI Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 37.4% to $92.06 per share while the index has... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 Low-Volatility Stocks We’re Skeptical Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
3 Small-Cap Stocks We Approach with Caution
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Presents a High Growth Momentum and Technical Breakout Opportunity ↗
ANI Pharmaceuticals (ANIP) shows strong earnings acceleration, robust sales growth, and bullish analyst revisions. With a top technical rating, it's forming a base near highs, signaling a potential... 
Via Chartmill
News headline image
3 Unpopular Stocks with Questionable Fundamentals
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
3 Russell 2000 Stocks with Questionable Fundamentals
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
News headline image
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Generic Pharmaceuticals Stocks Q2 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Best of the Bunch
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.